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Abstract Bone substitutes are being increasingly used in
surgery as over two millions bone grafting procedures are
performed worldwide per year. Autografts still represent the
gold standard for bone substitution, though the morbidity and
the inherent limited availability are the main limitations.
Allografts, i.e. banked bone, are osteoconductive and weakly
osteoinductive, though there are still concerns about the
residual infective risks, costs and donor availability issues.
As an alternative, xenograft substitutes are cheap, but their
use provided contrasting results, so far. Ceramic-based
synthetic bone substitutes are alternatively based on
hydroxyapatite (HA) and tricalcium phosphates, and are
widely used in the clinical practice. Indeed, despite being
completely resorbable and weaker than cortical bone, they
have exhaustively proved to be effective. Biomimetic HAs
are the evolution of traditional HA and contains ions (car-
bonates, Si, Sr, Fl, Mg) that mimic natural HA (biomimetic
HA). Injectable cements represent another evolution,
enabling mininvasive techniques. Bone morphogenetic
proteins (namely BMP2 and 7) are the only bone inducing
growth factors approved for human use in spine surgery and
for the treatment of tibial nonunion. Demineralized bone
matrix and platelet rich plasma did not prove to be effective
and their use as bone substitutes remains controversial.
Experimental cell-based approaches are considered the best
suitable emerging strategies in several regenerative medi-
cine application, including bone regeneration. In some cases,
cells have been used as bioactive vehicles delivering osteo-
inductive genes locally to achieve bone regeneration. In
particular, mesenchymal stem cells have been widely
exploited for this purpose, being multipotent cells capable of
efficient osteogenic potential. Here we intend to review and
update the alternative available techniques used for bone
fusion, along with some hints on the advancements achieved
through the experimental research in this field.
1 Introduction
Bone substitutes are being increasingly used especially in
oncologic surgery, traumatology, revision prosthetic sur-
gery and spine surgery [1]. Bone grafting frequency is
indeed the second most frequent tissue transplantation
worldwide, coming right after blood transfusion. Over two
millions bone grafting procedures are performed every
year, with more than 500,000 implanted in the US alone
[2–5]. This is due to their ease use and handling, improved
safety profiles, intraoperative cost and time advantages,
and adaptability to a variety of clinical challenges.
The incorporation of a bone graft is defined as the ‘‘pro-
cess of envelopment and interdigitation of the donor bone
tissue with new bone deposited by the recipient’’ [6]. This
process follows a typical multistep cascade: initially, the
bone graft produces a response leading to the accumulation
of inflammatory cells, followed by the chemotaxis of host
mesenchymal cells to the graft site. Thereafter, the primitive
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host cells differentiate into chondroblasts and osteoblasts, a
process under the influence of various osteoinductive factors.
The additional processes of bone graft revascularization and
necrotic graft resorption occur concurrently. Finally, bone
production from the osteoblasts onto the graft’s three-
dimensional framework occurs, followed by bone remodel-
ing in response to mechanical stress [7, 8].
A bone substitute can be defined as ‘‘a synthetic, inorganic
or biologically organic combination which can be inserted
for the treatment of a bone defect instead of autogenous or
allogenous bone’’ [9]. A wide variety of bone substitutes
have been employed over the past 50 years. Bone substitutes
can be broadly categorized into bone grafts (autograft,
allograft, xenograft), ceramics (hydroxyapatite, TCP, cal-
cium sulphate) and growth factors (DBM, PRP, BMP’S)
[10]. The ideal bone substitute should be biocompatible and
not evoke any adverse inflammatory response. It should be
easily molded into the bone defect within a short setting time.
It should be osteoconductive, osteoinductive [11] and re-
sorbable. It should be possibly traceable in vivo; to this aim
radiolucency is ideal to allow optimal radiographic assess-
ment. Also, the ideal bone substitute should be thermally
nonconductive, sterilizable, and readily available at a rea-
sonable cost [12].
Although autologous bone grafting is still considered the
‘‘gold standard’’ in bony defect repair, the past century has
seen significant advances in the development of valid
alternatives to natural bone.
The latter half of the twentieth century has seen the
evolution of the hydroxyapatite and calcium phosphate-
based cements and ceramics. Current advances are being
made with the development of tissue-engineered products,
incorporating growth factors and stem cells.
Depending on the type of surgery and on the bone loss,
many options are possible. Cortical strut grafts are used
were mechanic strength is needed. Spongy bone, often
morcelized, is more usefull to fill cavitary bone defects or
in spine fusion. Ceramics under granule, blocks, or mold-
able paste shape are normally used to enhance bone heal,
but have poor mechanical qualities and stable hardware
fixation is necessary. Growth factors are on the market as
moldable paste. BMPs are currently indicated only in tibial
non union (BMP-7) and spine surgery (BMP-2).
In this report we will review some of the most important
biomaterials in each of these categories.
2 Bone grafts
2.1 Autografts
Currently autografts are the ‘‘gold standard’’ in bone sub-
stitution [13, 14]. Autologous (or autogenous) bone
grafting involves utilizing bone obtained from the same
individual receiving the graft [15]. Bone can be harvested
from non-essential bones, such as the iliac crest or the
fibula (Fig. 1), the chin, the ribs, the mandible and even
parts of the skull. Autogenous bone possesses all the
properties essential for bone formation: it is osteoconduc-
tive and osteoinductive, and it houses growth factors and
osteogenic cells with no associated immune or infective-
related risks. Autologous bone fracts are slowly replaced
by newly formed host bone. The disadvantages of auto-
grafts reside in the inherent morbidity: (1) a surgical donor
site is required, leading to possible post-operative pain and
complications. [16, 17]; (2) a likelihood of blood loss or
hematomas, infection, fracture, neurovascular injury, as
well as cosmetic deformity, at the explantation site and
longer operative time.
Also, autogenous bone availability in a patient repre-
sents a significant limit, especially in pediatric patients and
in the elderly. An autograft may also be performed without
a solid bony structure, for example using bone reamed from
the anterior superior iliac spine. In this case there is an
osteoinductive and osteogenic action, however there is no
mechanical support action, as there is no solid bony
structure [18].
2.2 Allografts
Allograft biobanked bone represents a suitable alternative
to autogenous bone, being derived from humans as well.
Allograft bone can be collected from either living donors
(patients total hip replacement surgery) or nonliving donors
and must be processed within a bone tissue bank (Fig. 2).
Bone Tissue Banks fastly grew up since the’80 years but
doubts and concerns arise about costs and problems related
to storing [19].
Donor bone is osteoconductive, weakly osteoinductive
(growth factors may still be present, depending on the pro-
cessing). Also, allografts often require sterilization (gamma-
irradiation), with detrimental effects on mechanical proper-
ties of bone, and deactivation of proteins normally found in
healthy bone. Concerns on the potential infective risks were
raised, though since 1989 only 2 documented cases of HIV
were reported with a risk rate of 1:1.6 milions [20]. Anyway,
current procedure for donor bone procurement and pro-
cessing are designed to significantly limit the possible
transmission of knonw pathogens [21].
Other more important infective risk were reported on
HBV (1 case), HCV (2 cases), one fatal infection by
Clostridium Difficilis, and 26 bacterial infections [22–24].
The limits of such transplants are costs, laborious proce-
dure (tissue processing, harvesting), mechanical resistance
(in freeze dried and irradiated), limited osteoinduction and
risk of infection.
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2.3 Xenografts
Xenograft bone substitutes have their origin from a species
other than human, such as bovine bone (or porcine bone)
which can be freeze dried or demineralized and deprotei-
nized (Fig. 3). Bovine bone was first introduced by Maatz
and Bauermeister in 1957 [25]. Xenografts are usually only
distributed as a calcified matrix. Madrepore and or millepore
Fig. 1 a Cortical strut autograft from fibula in a proximal humeral non union treated by ORIF. b One year X-ray control show bone healing and
the persistence of the autograft
Fig. 2 a, b Morcelized homologous bone graft obtained from a banked femoral head. c Severe acetabular bone loss in a mobilized hip revision
cup. d X-ray control at 2 years with evidence of bony stable osseointegration of the new cup in the remodeled bone graft
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type of corals are harvested and treated to become ‘‘coral
derived granules’’ (CDG) and other types of coralline xe-
nografts [26]. Coral based xenografts are mainly calcium
carbonate (and an important proportion of fluorides, useful
in the context of grafting to promote bone development)
while natural human bone is made of hydroxyapatite along
with calcium phosphate and carbonate. The coral material is
thus either transformed industrially into hydroxyapatite
through a hydrothermal process, yielding to a non-resorb-
able xenograft, or simply the process is omitted and the
coralline material remains in its calcium carbonate state for
better resorption of the graft by the natural bone. The coral
xenograft is then saturated with growth enhancing gels and
solutions [27]. In January 2010 Italian scientists announced a
breakthrough in the use of wood as a bone substitute, though
this technique is not expected to be used for humans until at
the earliest 2015. Various species of wood are pyrolized in an
inert atmosphere, the carbonaceous residue is saturated with
calcium salts and finally reheated to obtain a highly porous
crystallized material of much higher porosity than trabecular
titanium or porous hard ceramic bone-substitutes; the
inventors claim the wood based material will permit better
penetration during bone growth and more flexion than metal
or hard ceramic grafts [28]. Xenografts have given good
results in dentistry, but scarce validation in orthopaedics.
Clinically available coral-based products are Interpore
and Pro-osteon (Interpore International, Inc., Irvine, CA) as
well as bovine derived products such as Bio-Oss (Geistlich
Biomaterials, Geistlich, Switzerland), Osteograf-N (Cera-
Med Co., Denver, CO), and Endobon (Merck Co.,
Darmstadt, Germany). Doubts were argumented regard
‘‘zoonose’’ diseases transmitted from animals to humans,
like BSE (Bovine spongiform Encephalopathy) or PERV
(Porcine Endogenous Retroviruses) [29].
Results are contradictory with some authors reporting
favourable data, but in the clinical practice xenografts are
scarcely used [30–34].
Moreover poor results in hip surgery, with 25 % of
pseudo infections complications, were recently reported
[35].
The advantages are the easy availability, the osteocon-
ductivity, the good mechanical properties and low costs.
3 Ceramics
Generally ceramics bone substitutes are calcium based
substitutes, a mix of HA (Hydroxyapatite) and TCP (Tri-
calcium.Phosphate), the amorphous phase of HA. HA is a
relatively inert substance that is retained ‘‘in vivo’’ for
Fig. 3 a, b Bovine bone substitute (Xenograft) in chips and blocks shape. c The xenograft is clearly visible and not resorbed in a well bone
healed proximal humeral fracture at 1 year of follow up. d Acetabular bone defect filled with the same material
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prolonged periods of time, whereas the more porous TCP
typically undergoes biodegradation within 6 weeks of its
introduction into the area of bone formation. HA achieve
very high mechanical strenght, while TCP has poor
mechanical qualities. Generally the base is a biphasic cal-
cium phosphate, which combine 40–60 % TCP with
60–40 % HA, that may yield a more physiological balance
between mechanical support and bone resorption [36].
A level II and a level IV study found lesser pain,
operating time, blood loss and complication in synthetic
substitutes compared with iliac crest grafts [37]. Ceramics
are widely known and are proved to be safe and effective in
bone substitution. HA-TCP are now available in form of
blocks, granules, and injectable kits. Macroporosity of
about 100–400 l and interconnected porosity are necessary
for bone ingrowth. Depending on the concentration of HA
and TCP the strength is variable between 10 and 60 MP
that is very lower than cortical bone compression strength
(150–200 MP), and this is one of the major limit of cera-
mic based biomaterials.
4 Hydroxyapatite and tricalcium phosphate
Hydroxyapatite [Ca10(PO4)6(OH)2] (HA) is the cristalline
form of tricalcium phosaphate (TCP) and is the primary
mineral component of teeth and bone. For the past 30 years,
it has been popular in orthopaedic, craniofacial and orthog-
nathic surgery, filling bony defects and smoothing contour
irregularities. HA ceramics come in both naturally and
synthetic forms. HA and TCP ceramics are manufactured in a
variety of forms including granules and porous blocks
(Fig. 4). TCP is more soluble than HA. Although HA
accounts for nearly 70 % of the mineral content of teeth and
bone, the occurring HA in the human body exists in a
substituted form. Carbonate, silicates, and magnesium
among other ions, may replace hydroxyl or phosphate groups
of the apatite structure. Investigators have attempted to
produce alginate [38], strontium [39], silicon [40], carbonate
and magnesium [41–46] substituted synthetic HA in an effort
to produce HA that more closely resembles the mineral
content of native bone, enhancing bioactivity and osteo-
conduction (Biomimetic ceramic substitutes) [47]. Although
there are few of products made of biomimetic HA in the
clinical use at this time, the research is ongoing on this
direction and biomimetic HA substitution will likely remain
one of the most promising area of research.
5 Calcium phosphate cements
Calcium phosphate cements (CPC) are synthetic bone
substitutes that were invented in 1986 by Chow and Brown,
scientists at the American Dental Association [48]. The
cements are a white powder, consisting of calcium phos-
phate, that when mixed with a liquid, forms a workable
paste which can be shaped during surgery to fit the con-
tours of bone loss. The cements harden within 20 min. The
hardening reaction, which forms nanocrystalline hydroxy-
apatite (HA) is isothermic and occurs at physiologic pH so
tissue damage does not occur during the setting reaction.
CPCs were FDA approved for the treatment of non-load-
bearing bone defects in 1996. HA is the primary inorganic
component of natural bone which makes the hardened
cement biocompatible and osteoconductive. Over time,
CPCs are gradually resorbed and replaced with new bone.
Because CPCs are brittle, they are used for non-load-
bearing applications such as dental, cranio-facial and
orthopaedic applications. CPCs have two significant
advantages over pre-formed, sintered ceramics. First, the
CPCs paste can be sculpted during surgery to fit the cavi-
ties. Second, the nanocrystalline hydroxyapatite structure
of the CPC makes it osteoconductive causing it to be
gradually resorbed and replaced with new bone. CPCs are
injectable and were recently introduced in the clinical
practice to adjuvate minimally invasive procedures (MIS)
and tissue Sparing surgery (TSS) in order to reduce mor-
bidity and costs (Fig. 5). The first cement that was intro-
duced on the market in the late 1990s was the Norian, by
Cupertino (Synthes-De-Puy), a self hardening carbonate
HA, even known as ‘‘Dhallite’’ [49].
From then many other phosphate cements were pro-
posed for clinical practice, like Bonesource (Stryker),
Calcibone (Biomet), CrhonOs (Synthes), Hydroset (Syn-
thes) [50], Sintlife (Finceramica) [47], KyphOs
(Medronic).
Recently the research on CPC has focused on improving
mechanical properties, making premixed cements, making
the cement macroporous and seeding cells and growth
factors into the cement.
6 Calcium sulphate
Calcium sulphate (CS), even known as ‘‘gypsum’’ or
‘‘Plaster of Paris’’, was firstly implanted in humans as a
void filler of tubercolous osteomyelitis by Dreesman in
1892 [51]. More recently it was reintroduced in the clinical
practice as a bone substitute by Peltier in 1959, in a more
pure and crystalline form [52–54] CS is resorbed variably
within 6–8 weeks. Proponents of calcium sulfate claim that
the pellets provide an effective gap filler, allow for vascular
ingrowth, and resorb rapidly and completely, allowing for
physiologic bone healing [55]. Apparently due to rapid
graft resorption, the resulting calcium-rich fluid incites
inflammation. First reports showed very promising results
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in vitro [56] and ‘‘in vivo’’: Huff and Grisoni in the mouse
[57], Cunningham in the sheep [58], Hadjiipavlou in the
sheep [59], Turner in the dog [60], and also in humans [61,
62]. Recently many adverse or no effects were reported,
mainly explained because of the too fast resorption and the
production of a similar inflammatory reaction without bone
formation (13–18 %) [63–67] (Fig. 6). Subsequently CS
was proposed as a scaffold for demineralized bone matrix
(DBM). The mixture with CS enhanced the clinical out-
come more than calcium sulfate alone.
7 Polymer-based bone graft substitutes
Polymers have physical, mechanical, and chemical prop-
erties completely different from the other bone substitutes.
The polymers can be divided into natural polymers and
synthetic polymers. These, in turn, can be divided further
into degradable and nondegradable types.
One of the most important natural polymer in bone is
collagen.
Cortoss is an injectable resin-based product with appli-
cations for load-bearing sites [68]. It consists of 33 %
difunctional methacrylates that form a highly cross-linked
3-dimensional polymer, reinforced with 67 % radiopaque
and bioactive glass ceramic particles. Initial results using
Cortoss in vertebroplasty for osteoporotic and metastatic
vertebral compression fractures were encouraging [69].
Degradable synthetic polymers (i.e., natural polymers)
are resorbed by the body. The benefit is that they enhance
healing without remaining foreign bodies. Degradable
polymers such as polylactic acid and poly(lactic-co-gly-
colic acid) have been used as standalone devices and as
extenders of autografts and allografts.
Fig. 4 HA-TCP bone substitutes in proximal humeral and tibial
traumatic bone loss. a Intraoperatory implant of the material in the
proximal humerus. b X-ray control at 1 year show the substitute
inside the humeral head. c–f X ray and CT scan at 3 year of follow up
in the proximal tibia. The HA-TCP material resulted well osseoin-
tegrated, but without any sign of resorption or bone substitution
2450 J Mater Sci: Mater Med (2014) 25:2445–2461
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Most research has been directed to poly lactic acid
(PLA), poly glycolic acid (PGA) and poly lactic-co-gly-
colide (PLGA) copolymers. Tissue Regeneration Thera-
peutics (Toronto, Canada) has developed a porous poly
(lactic-co-glycolic acid) foam matrix by using a particu-
late-leaching process to induce porosity. It is currently
marketed under the trade name OsteoScaf. Immix (Osteo-
biologics, Smith and Nephew, Memphis, Tennessee) and it
is used as a graft extender [70].
The success of these has further led to the evaluation
of aliphatic polyesters such as polye-caprolactone (PCL).
It appears as semicrystalline polyester and is highly pro-
cessable as it is soluble in a wide range of organic sol-
vents. The uncommon things of PCL is its high thermal
stability, with decomposition temperature (Td) of 350 C,
whereas others aliphatic polyesters are between 235 and
255 C [71]. In bone engineering, PCL can be categorized
as a promising biocompatible and biodegradable polymer
since it is being used to enhance bone ingrowth and
regeneration in the treatment of bone defects [72, 73],
however, PCL is poorly used due to the slow degradation
time [74].
8 Composite materials
8.1 Composite of collagen and hydroxyapatite
Bone is mainly made of collagen (Col) and carbonate
substituted hydroxyapatite (HA). Actually it is possible to
obtain Col–HA by a self assembling process on a nano-
metric scale [75].
Thus, an implant manufactured from such components is
likely to behave better than other bone substitutes made as
monolithic devices. Indeed, both collagen type I and
hydroxyapatite were found to enhance osteoblast differ-
entiation [76], but combined together, they were shown to
accelerate osteogenesis. A composite matrix when
embedded with human-like osteoblast cells, showed better
osteoconductive properties compared to monolithic HA
and produced calcification of identical bone matrix [77,
78]. In addition, Col-HA composites proved to be bio-
compatible both in humans and in animals [77, 79].
Moreover these composites have some mechanical advan-
tages. The ductile properties of collagen help to increase
the poor fracture toughness of hydroxyapatites. The
Fig. 5 Injectable TCP cement
bone substitutes: a–b injectable
cements have the advantage to
be mouldable and contourable
to the bone loss in mininvasive
or open surgery; c bone loss in a
distal tibial open fracture
delayed union (CT scan);
d 1 year X-ray control, showed
bone consolidation and
osseointegration of the TCP
cement
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addition of a calcium/phosphate compound to collagen
sheets gave higher stability, increased the resistance [80]
and enhanced the mechanical ‘wet’ properties [81]. The
direct comparison of other materials compared with Col–
HA composites for bone substitutes have yet to be clearly
investigated. However, increasing the biomimetic proper-
ties of an implant may reduce the problems of bacterial
infections associated with inserting a foreign body [82].
Evidence of the biological advantage compared to artificial
polymeric scaffolds have been further demonstrated in
cartilage regeneration [83]. The addition of collagen to a
ceramic structure can provide other additional advantages
to surgical applications: shape control, spatial adaptation,
increased particle and defect wall adhesion, and the capa-
bility to favor clot formation and stabilization [79].
Healos (DePuy Orthopaedics, Inc, Warsaw, Ind) is a
natural polymer-based product, a polymer-ceramic
composite consisting of collagen fibers coated with
hydroxyapatite and indicated for spinal fusions [84].
In summary therefore, combining both collagen and
hydroxyapatite should provide an advantage over other
materials for use in bone tissue repair [85]. Further clinical
studies are required to validate its effectiveness.
9 Growth factors
9.1 Demineralized bone matrix
The aseptical processing of banked donor bone to produce
human demineralized bone matrix (DBM), was first
described in 1975 [86] and introduced in the orthopedic
and periodontal practice since the early 1980s. The decal-
cified bone(residual calcium \5 %) is mainly represented
Fig. 6 Calcium sulphate (CS):
a Pellets fill the residual gap
after DHS explant in a healed
intertrochanteric fracture.
b Two months after the CS was
totally resorbed. c Antibiotic
loaded CS pellets in a tibial
osteomyelitis. d Three years CT
scan control do not show any
evidence of bone regeneration.
No signs of CS were founded
while the infection was healed
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by the collagen matrix that is supposed to replicate the
tridimensional architecture of bone, hence facilitating and
guiding host cell invasion, growth and differentiation [87].
Moreover DBM should retaining bone-inducing growth
factors, such as bone morphogenetic proteins (BMP),
insulin growth factor (IGF), transforming growth factor
(TGF), fibroblast growth factor (FGF), able to stimulate
activation and migration of osteogenic stem cells and
progenitor cells, and to induce revascularization. None-
theless, DBM lacks of any mechanical strength, hence are
used exclusively for filling purposes and normally are
associated with carriers like glycerol (Grafton-Osteotech),
calcium sulphate (Allomatrix-Whright), hyaluronic acid
(DBX-Synthes), porcine collagen (Osteofil- Medtronics-
Sofamor Danek), carbossimetilcellulose (Dynagraft- Gen-
Sci Regeneration Sciences) (Fig. 7). Despite a copious
amount of literature data reports the effectiveness of DBM,
mostly in preclinical studies [20], as a safe and effective
bone grafting material [88], there is still limitate evidence
produced in Level 1-2 studies, to support the use of DBM
as a stand-alone bone substitute [89].
Moreover, concerns were raised about the extreme
variability in BMP 2 and BMP 7 content in different
commercially available DBM lots, which may be due to the
absence of standardized processes for production along
with donor-related issues [89, 90].
9.2 Platelet rich plasma (PRP)
Blood platelets are easily collected from blood and repre-
sent a valuable source of growth factors, such as the
platelet derived growth factor, the insulin-like growth
Fig. 7 Demineralized Bone
Matrix (DBM): a–c Complex
proximal humeral fracture
treated by ORIF, DBM and
calcium sulphate (Allomatrix-
Wright); d One year follow up
demonstrate good consolidation
of the fracture
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factors, and the transforming growth factors [91–93].
Platelet-rich plasma (PRP) is easily obtained by concen-
tration of autologous blood platelet through gradient den-
sity centrifugation (Fig. 8). PRP proved to exert
chemotactic and mitogenic properties for osteoblast and
fibroblast cells in vitro, to stimulate fibroblast hyaluronate
synthesis, a pre requisite for the formation of the extra-
cellular matrix, thereby enhancing bone formation [94–98].
Unfortunately, diverse clinical studies so far reported
unsuccessful results in spine surgery, with a decreased
incidence of spine fusions (15–19 %), even when used in
combination with bone marrow cells [99]. This failure
was believed to be due to a paradoxical inhibitory effect
on BMP 2 at high concentrations [100–102]. Indeed,
currently PRP is not validated as a stand-alone bone
substitute but is rather considered a co-growth factor for
bone healing.
9.3 Bone morphogenetic proteins
Originally identified and named after their ability to induce
ectopic bone formation [103], bone morphogenetic proteins
(BMPs) represent a wide and heterogeneous family of
highly conserved secreted proteins, within the transforming
growth factor-b superfamily, deeply involved in the skel-
etogenic process [104, 105].
Selected BMPs appear to promote in vitro bone forma-
tion by: inducing the differentiation of pluripotent me-
senchimal cells towards the chondrogenic and osteogenic
lineages, stimulating angiogenesis and alkaline phospha-
tase activity [94]. The osteogenic/osteoinductive potential
of the BMPs was strongly validated in both preclinical and
clinical studies, generally reporting performance that were
comparable to autogenous cancellous bone, with fusion
rates between 80 and 99 % [106–112].
To date, only the use of recombinant human BMP2 and
BMP7 has been approved both in Europe and the United
States for selected clinical applications: BMP 2 with a
collagen carrier (INFUSE, Medtronic Sofamor Danek,
Minneapolis) for lumbar vertebral interbody fusion and
BMP 7 (OP-1, Stryker, Kalamazoo, Michigan) for tibial
non union, in patients who underwent previous unsucces-
full treatments. Dark and lights persist also due to the
variable needed dosage, which may be patient- and site-
dependent, and to the still high costs, which makes their
use prohibitive in most settings. In addition, BMPs showed
adverse effect in cervical spine and are hence contraindi-
cated in this application [113].
Fig. 8 Platelet Rich Plasma (PRP): a–d autologous blood is obtained in the operating room. After centrifugation the different components are
differentiate. e, f A platelet concentrate is obtained for injection or deposition into the bone gap or wound
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10 Emerging strategies for bone substitution
10.1 Biomimetic and smart materials in bone tissue
engineering
The challenge to tissue engineers is to design and develop
temporary bone scaffolds which deliver bioactive mole-
cules and drugs or cells to the injury site and hence extend
its biological functionality (accelerate healing and tissue
regeneration while simultaneously preventing pathology).
Although mimicking the geometric architecture of bone in
a synthetic scaffold has been shown to promote favorable
cellular activity, the overall capacity for a scaffold to direct
cell behavior can be substantially improved through the
controlled delivery of bio specific cues [114–119].
Administration of growth factors and other bioactive
molecules to promote bone formation and repair has
achieved promising results in several preclinical and clin-
ical models [120–125]. A variety of administration meth-
ods have been investigated including: bolus injection,
surface adsorbed protein release, osmotic pumps, and
controlled release from biodegradable scaffolds. The effi-
cacy of the delivery vehicle relies on its ability to provide
the appropriate dose over the appropriate therapeutic time.
Ideally, the presentation of bioactive molecules or drugs
must be finely tuned to dynamically match the physiolog-
ical needs of the tissue as it regenerates. Because of the
hydrolytically unstable linkages in their backbone and
tunable biodegradation rate, polymers have demonstrated
to be effective. Ceramic materials have also demonstrated
the ability to biodegrade and release bioactive molecules at
a controlled rate [126–130]. Natural polymers such as
collagen, fibrin, alginate, gelatin, and GAGs have also been
extensively investigated as drug delivery vehicles in bone
tissue engineering. These natural polymers have distinct
advantages due to their inherent biocompatibility and
bioactivity but lack the mechanical properties required for
load bearing applications, may have inappropriate (fixed)
degradation rates, are difficult to harvest and sterilize, and
may induce an immunogenic response. Bioactive mole-
cules can be covalently bound to polymers or physically
entrapped inside a polymer matrix [131, 132]. In either
case, the molecule is released as the polymer degrades in
the physiological environment.
Aliphatic polyesters such as poly(lactic-acid)(PLA),
poly(glycolic-acid)(PGA), and poly(caprolactone) (PCL),
and their copolymers are the most commonly utilized
polymers in bone tissue engineering [133–135]. Both PGA
and PLA scaffolds has been investigated as a slow-delivery
carrier for growth factors in several ‘‘in vitro’’ and
‘‘in vivo’’ studies, and demonstrated the ability to promote
healing and osseointegration compared with control scaf-
folds [136–138]. Researchers combine multiple polymers
in a chemical process called copolymerization to gain more
control over the degradation rate, hydrophobicity, crystal-
linity. Copolymerization is analogous to the design of
composite materials where multiple constituents are com-
bined resulting in a new material with desirable properties
from each constituent. Undoubtedly, the most commonly
utilized copolymer for bioactive molecule encapsulation
and release for bone tissue engineering is the copolymer
poly(lactic acid-co-glycolic acid) (PLGA). Several
researchers have utilized this well-characterized copolymer
for encapsulation and release of a wide variety of bioactive
molecules and drugs including TGF-b, BMPs, IGFs,
VEGF, NGF, DNA, vancomycin, gentamycin, cisplatin,
and others [139–146]. However, although PLGA has
shown to be promisinge in bone scaffold applications, its
clinical utility is limited due to its relatively poor
mechanical properties (specifically Young’s Modulus)
compared with cancellous bone, and therefore must be
combined with other materials to enhance its mechanical
properties [147].
Many synthetic bone scaffolds rely on the delivery of
single factors, which may partially explain the limited
clinical utility of many current approaches [140]. There-
fore, researchers have been investigating techniques to
encapsulate and release multiple bioactive molecules in a
highly controlled spatial and temporal manner. Research
has shown that this method significantly enhances tissue
regeneration compared with the controlled release of single
biological cues [148–150]. The technology of incorporat-
ing multiple chemical effectors and controlling their spatial
and temporal release is a very promising strategy, but is
still experimental and has not yet demonstrated widespread
preclinical or clinical utility to date.
The failure to identify either a single material or growth
factor as the panacea for bone regeneration, or a biological
scaffold that will promote integration and vascularization,
has led to an increased interest in optimizing biomaterials
to promote specific cell-biomaterial interactions. For
example, Arg–Gly–Asp (RGD) sequence peptides
(involved in integrin-mediated cell adhesion) can be
incorporated onto the scaffold surface to enhance cell
adhesion and spreading [151]. Yang et al. [152] have
demonstrated the potential to promote human osteopro-
genitor differentiation on RGD-coupled biodegradeable
scaffolds.
More recently drug delivery techniques such as entrap-
ment within a hydrogel matrix allowing growth factors to
be released in a controlled fashion from the scaffold to aid
the regenerating tissue have been applied [153–156]. Such
approaches are appealing as they avoid the use of solvents,
and high temperatures (and therefore protein degradation)
and subsequent release of the growth factor is controlled, in
response to environmental stimuli. This strategy has been
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employed in bone tissue engineering, where rhBMP-2
[157] basic fibroblast growth factor [155] and vascular
endothelial growth factor [156] have all been successfully
incorporated into a hydrogel prior to in vivo implantation.
Supercritical fluid technology has evolved as a promising
approach in the development of porous biodegradable
scaffolds for tissue engineering [158]. The absence of
solvents and thermal processing makes this an attractive
approach to growth factor incorporation and Howdle and
colleagues have demonstrated high protein (ribonuclease)
loading into foamed PLA scaffolds which retained full
activity on subsequent release from the PLA over 3 months
[153, 159]. This technology could provide a simple one-
step process to the difficulties of incorporating growth
factors and/or guest particles (such as hydroxyapatite) into
a controlled release delivery system.
New strategies works to encapsulate and release drugs
which prevent pathologies that can occur post implantation
of a synthetic scaffold. A wide variety of drugs have been
encapsulated and released from biodegradable polymer
scaffolds including antibiotics, DNA, RNA, cathepsin
inhibitors, chitin, chemotherapeutics, bisphosphonates,
statins, sodium fluoride, dihydropyridine, and many others
[160–164]. Researchers are aggressively pursuing strate-
gies to deliver antibiotics locally to the site of injury/sur-
gery. The most common biodegradable polymer/antibiotic
combination is PLGA scaffolds loaded with antibiotics
such as ciprofloxin, gentamycin, and vancomycin [165,
166]. PLGA scaffolds have demonstrated successful sus-
tained local delivery of these antibiotics for up to 20 or
more days in vitro and in preclinical animal models [141,
142, 167–169]. Although local delivery of antibiotics has a
very promising outlook, there remains a number of chal-
lenges (such as antibiotic stability within the scaffold and
antibiotic deactivation during fabrication), which need to
be addressed before clinical trials can begin [170].
10.2 Cell-based and gene therapy
The challenges offered by current bone grafting techniques
have been driving the intensive research efforts spent
during the last decades to develop new approaches and
technologies. To this aim, cell-based gene therapy has
attracted great interest from the scientific community,
representing a tentative approach to achieve bone substi-
tution [171]. In gene therapy approaches, cells are used as
bioactive vehicles delivering osteoinductive genes locally
to achieve bone regeneration. Different molecules have
been tested to this aim, mainly represented by genes
belonging to the BMP family and related cascade [172].
Indeed, genetically engineered cells are believed to main-
tain physiologic doses of a gene product for a sustained
period once inoculated into the selected anatomical site,
facilitating an efficient bone healing [173]. In addition, the
overwhelming amount of data that have been clarifying the
whole molecular scenario orchestrating osteogenesis and
bone healing, provided new osteoinductive molecules to be
tested as potential therapeutics [174]. Cell-based gene
therapy approaches based on engineered-osteoinductive
cells allowed achieving the most convincing results in
terms of bone healing in animal models [172, 174, 175].
Though, a number of safety issues currently limit the use of
genetic engineering procedures, based on viral and nonviral
vectors, in the clinical setting. Thus, strictly-named gene
therapy approaches for bone regeneration ceased to repre-
sent suitable for translational purposes.
Cell-based approaches are mainly based on mesenchy-
mal stem cells (MSCs), that have been widely employed, in
conjunction with appropriate osteoinductive scaffolds, and
considered the most effective bioactive bone substitutes
‘‘in vivo’’ [172, 176, 177].
MSCs are multipotent stem cells that are capable of
extensive self-renewal, plasticity and multilineage potential
[178, 179]. These cells resides in the stroma of bone
marrow and other organs and tissues (fat, muscle, skin,
synovial membrane, tendons lung, etc.); hence they are also
named ‘‘stromal stem cells’’ [180]. The great advantages of
MSCs reside in the ease of isolation and ‘‘ex vivo’’
expansion, preserving their plasticity and self-renewal
potential [181]. Upon appropriate in vitro induction, MSCs
can be differentiated along the osteogenic lineage. MSC
derived from bone marrow showed a high potential for
osteogenic differentiation, which has been exploited for
cell-based therapy of congenital bone disorders [182–184].
The proposed use of MSCs in orthopedic surgery comes
also from their immunomodulatory properties, that make
them potentially suitable for allogenic transplantation
[185].
It is noteworthy that naı¨ve undifferentiated MSCs are
prone to environment-induced lineage commitment [186]
meaning that they can undergo spontaneous osteogenic
differentiation upon ‘‘in vivo’’ inoculation into a damaged
bone [187, 176]. This feature may suggest their safe use as
it does not imply any kind of ‘‘ex vivo’’ osteogenic
induction prior to ‘‘in vivo’’ inoculation. Nonetheless, the
production of clinical-grade MSCs, requires dedicated cell
factories for their ‘‘ex vivo’’ large scale culture amplifica-
tion; these are GMP-proof facilities that need to comply to
the same regulations required for the drug manufacturing
industries, as culture-amplified cells, according to Euro-
pean tissue banking rules, are considered as medicinal
products [21, 188].
Few active clinical trials are currently ongoing that
exploit MSC-based treatment as bone regenerative strate-
gies (www.clinicaltrials.gov) [189].
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11 Conclusions
Bone loss persists to be an important challenge in surgery,
and many alternatives are available. Despite the improve-
ment of research, human bone grafts persist to be the most
effective bone substitutes to replace bone loss. Alternatives
to bone grafts lacks of one or more of the concepts of the
‘‘Diamond theory’’ of Giannoudis: osteogenic cells and
vascularization, mechanical stability, growth factors, os-
teoconductive scaffolds (in combination with growths
factors), that are a prerequisite for bone healing [190].
Moreover most alternatives are expensive and not validated
by EBM, thus being scarcely recommendable for clinical
use. Actually, ceramics substitutes are the best for safeness,
effectiveness and costs. BMP 2 and BMP 7 are EBM
validated, for specific use, but costs are elevated. Other
techniques or alternatives are expensive, and not validated,
thus needing standard randomized clinical trials prior to be
approved for routinely clinical use.
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